HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma

Mandrioli, Roberto; Saracino, Maria Addolorata; Ferrari, Silvia; Berardi, Domenico; Kenndler, Ernst; Raggi, Maria Augusta

doi:10.1016/j.jchromb.2006.03.026

Cited by 48 publications

(30 citation statements)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plasma samples were quickly separated in a centrifuge and stored at À808C until assayed. The plasma levels of sertraline and desmethylsertraline were analyzed by highperformance liquid chromatography (HPLC) accord-ing to the method of Mandrioli et al (2006). In short, solid-phase extraction was carried out using Varian BondElut C2 cartridges (100 mg, 1 ml) on a Varian VacElut apparatus.…”

Section: Methodsmentioning

confidence: 99%

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Yoshimura

Umene-Nakano

Ueda

et al. 2008

Human Psychopharmacology

View full text Add to dashboard Cite

In the present study, we examined the efficacy of risperidone addition on sertraline-resistant depressed patients and the effects of risperidone on the metabolism of sertraline. Ten patients (M/F: 4/6, age: 54 +/- 10 years) met the DSM-IV criteria for major depressive disorder enrolled the study. Hamilton Dating Scale for Depression (HAM-D) scores (mean +/- SD) in all 10 patients significantly decreased from 19 +/- 4 (before risperidone addition) to 11 +/- 3 (4 weeks after risperidone addition). Plasma levels of sertraline and desmethylsertraline did not change after risperidone addition. Serum BDNF levels in responders to risperidone addition were changed from 8.1 +/- 2.7 ng/ml (before risperidone addition) to 11.5 +/- 0.9 ng/ml (4 weeks after risperidone addition); in contrast, those in nonresponders changed from 7.8 +/- 2.2 ng/ml (before risperidone addition) to 7.9 +/- 2.4 ng/ml (4 weeks after risperidone addition). These results suggest that the addition of risperidone to sertraline is effective and well tolerated for sertraline-resistant depressive patients, which is accompanied with the increase in serum BDNF levels in responders to the risperidone addition, and the addition of risperidone to sertraline does not seem to influence sertraline metabolism.

show abstract

Section: Methodsmentioning

confidence: 99%

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Yoshimura

Umene-Nakano

Ueda

et al. 2008

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The method was validated in terms of precision and accuracy; the use of LIF detector, together with a suitable derivatisant, grants high sensitivity and selectivity for the analysis of SRT and DMS, which counterbalances the time cost and procedure needed for analyte derivatization. Compared to our previously developed method [11], the method presented is more selective, sensitive and has shorter analy- sis times. Finally, the method was successfully applied to the analysis of plasma samples from patients under therapy with SRT, allowing accurate determination of SRT together with the metabolite DMS.…”

Section: Discussionmentioning

confidence: 97%

“…Since the analytes are to be determined in human plasma, the derivatization procedure for LIF detection follows a sample clean-up procedure. An SPE procedure for the simultaneous HPLC analysis of SRT and DMS in human plasma has been recently developed in our laboratory [11]; this protocol was adopted as a starting point for the present method, especially concerning its suitability for the derivatization procedure. After loading 500 mL of plasma in the RP C2 cartridge, elution with MeOH (1 mL) and drying of the eluate, it was necessary to introduce some changes in the assay to make it suitable for the following derivatization procedure.…”

Section: Sample Pretreatmentmentioning

confidence: 99%

“…Some methods can be found in the literature for SRT analysis by HPLC [8][9][10][11][12][13][14], GC [15,16] or CE [17][18][19][20][21][22][23]. SRT was determined in plasma by HPLC-DAD [8], together with DMS by HPLC with UV [9][10][11] and fluorimetric detection after derivatization with dansyl chloride [12]. HPLC coupled to MS has also been used for pharmacokinetic purposes [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of sertraline and N‐desmethylsertraline in human plasma by CE with LIF detection

et al. 2007

Self Cite

View full text Add to dashboard Cite

A method has been developed for the analysis of the antidepressant drug sertraline together with its main metabolite N-desmethylsertraline (DMS) in human plasma. It is based on CE with LIF detection (lambda = 488 nm). A SPE procedure is employed for biological sample pretreatment, followed by a derivatization step with FITC; reboxetine was the internal standard. The effect of CD, acetone and N-methyl-D-glucamine (GLC) as constituents of the BGE for analyte separation was investigated. The final BGE consisted of 20 mM carbonate buffer, pH 9.0, with 2.5 mM heptakis(2,6-di-O-methyl)-beta-CD, 50 mM GLC and 20% v/v acetone. With 30 kV applied voltage, the electrophoretic run is completed in 7.5 min. Linearity was observed in the plasma concentration range from 3.0 to 500 ng/mL for sertraline and 4.0 to 500 ng/mL for DMS. Extraction yield was >97.1%, precision - expressed as RSD% - was <3.7, accuracy (recovery) was >95.6%. Due to its sensitivity and selectivity, the method was suited for the analysis of plasma samples from patients undergoing therapy with sertraline.

show abstract

“…For an investigation of SER in pregnancy, development of a precise, cost-effective, yet simple method was required for the analysis of the drug and its N-desmethylated metabolite norsertraline (NOR) in serum from women across their pregnancies. Although NOR is less effective than SER, it is an active metabolite with a relatively high serum levels due to its longer half life [4,5]. Pharmacokinetic results from the study have been previously published along with a brief preliminary description of the analytical method used [6].…”

Section: Introductionmentioning

confidence: 99%

LC–MS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase

et al. 2011

View full text Add to dashboard Cite

A sensitive liquid chromatography-mass spectrometry method for the simultaneous determination of sertraline (SER) and its major metabolite norsertraline (NOR) from serum was developed and validated in the context of a pharmacokinetic study in pregnant women. The separations were achieved on a silica column with a non-aqueous polar mobile phase consisting of acetonitrile, methanol and ammonium acetate at a flow rate of 0.5 mL min -1 . The concentrations were measured using a single quadruple mass spectroscopic detector supplied with atmospheric pressure ionization electrospray. Sample preparation consisted of a simple liquid-liquid procedure. The detector was set in selective ion mode for each compound of interest, 306 m/z for SER and 275 m/z for NOR. Calibration curves were generated by least square linear regression for concentration of 5-160 ng mL -1 for SER and from 10 to 320 ng mL -1 for NOR. The curves for both compounds of interest were linear, with correlation coefficients r 2 C 0.999.

show abstract

HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma

Cited by 48 publications

References 19 publications

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Addition of risperidone to sertraline improves sertraline‐resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Determination of sertraline and N‐desmethylsertraline in human plasma by CE with LIF detection

LC–MS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase

Contact Info

Product

Resources

About